CorMedix: A Shrinking Core And No Proven Second Engine [Seeking Alpha]
CorMedix Inc. (CRMD)
NASDAQ:AMEX Investor Relations:
cormedix.com
Company Research
Source: Seeking Alpha
FY26 guidance of ~$310M (midpoint) masks underlying deceleration, as DefenCath declines from $258.8M in FY25 to $150M–$170M in FY26, with the year-end run rate likely materially weaker heading into FY27. Rezzayo and DefenCath TPN offer long-term optionality but lack current financial contribution, while Melinta provides stability rather than growth. Despite low valuation multiples, limited forward visibility and the absence of a proven growth engine make the stock a “show-me” story rather than a compelling investment. sasirin pamai/iStock via Getty Images Investment Summary The core of CorMedix's ( CRMD ) thesis relies on whether the business can soon find its second growth engine. DefenCath, CorMedix's core business, generated $258.8M of revenue in FY25 but is
Show less
Read more
Impact Snapshot
Event Time:
CRMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRMD alerts
High impacting CorMedix Inc. news events
Weekly update
A roundup of the hottest topics
CRMD
News
- CorMedix Outlines Post-Melinta Growth, Q2 REZZAYO Phase 3 Catalyst and DefenCath Reimbursement Shift [Yahoo! Finance]Yahoo! Finance
- CorMedix to Participate in Needham Virtual Healthcare ConferenceGlobeNewswire
- CorMedix: Waiting On Phase III ReSPECT For A Further Re-Rating (Upgrade) [Seeking Alpha]Seeking Alpha
- How The CorMedix (CRMD) Investment Story Is Shifting As Analyst Targets Reset [Yahoo! Finance]Yahoo! Finance
- CorMedix CEO touts Melinta pivot, DefenCath TDAPA transition and Q2 REZZAYO Phase 3 data at Leerink [Yahoo! Finance]Yahoo! Finance
CRMD
Earnings
- 3/5/26 - Miss
CRMD
Sec Filings
- 4/17/26 - Form PRE
- 3/26/26 - Form SCHEDULE
- 3/6/26 - Form 8-K
- CRMD's page on the SEC website